Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,525 recalls · Class III, newest first

Class III · Low risk

Oxygen

CGMP Deviations: Cylinders filled using out of date gauges.

Terminated cGMP deviation Medical Park Homecare, Inc D-0776-2016
Class III · Low risk

Triamcinolone Diacetate Injectable Suspension

Labeling: Incorrect or Missing Lot and/or Exp Date: some vials may be mislabeled with an incorrect "Compounded" date, lot number, and "Do Not Use Beyond" date or BUD (Before Use Date) that may be longer than intended.

Terminated Labeling / mix-up Isomeric Pharmacy Solution, LLC D-0728-2016
Class III · Low risk

Clonazepam Tablets

Failed Impurities/Degradation Specifications: out of specification result for known impurity at 6 month timepoint.

Terminated Impurity / degradation Mylan Institutional, Inc. (d.b.a. UDL Laboratories) D-0650-2016
Class III · Low risk

Virt-Nate Prenatal/Postnatal

Tablets/Capsules Imprinted with Wrong ID; product debossed with an incorrect punch. Bottles could contain tablets debossed with V259 (debossing for PreTab) instead of the correct punch, V264 (debossing for Virt-Nate).

Terminated Labeling / mix-up Virtus Pharmaceuticals, Llc D-0775-2016
Class III · Low risk

NORepinephrine Bitartrate

Subpotent Drug; confirmed results by FDA analysis after customer complaints of discoloration

Terminated Wrong potency / content Pharmedium Services, LLC NDC 61553-127-61 D-0778-2016
Class III · Low risk

NORepinephrine Bitartrate

Subpotent Drug; confirmed results by FDA analysis after customer complaints of discoloration

Terminated Wrong potency / content Pharmedium Services, LLC NDC 61553-134-61 D-0777-2016
Class III · Low risk

Ranitidine Syrup

Failed Impurities/Degradation Specifications: Product recalled due to elevated impurity result detected during routine stability testing.

Terminated Impurity / degradation Bio-pharm, Inc. NDC 23155-291-51 D-0809-2016
Class III · Low risk

Lindane Lotion

Super-Potent Drug: Out of Specification Assay test results were reported for stability samples.

Terminated Wrong potency / content Morton Grove Pharmaceuticals, Inc. NDC 60432-833-60 D-0571-2016

Recalls by year